The Regal Partners Ltd (ASX: REG) share price is in focus today after the company reported preliminary 1H26 results, with normalised NPAT expected to double to at least $90 million and record net FUM inflows of over $1.3 billion for the half.

What did Regal Partners report?

• Normalised NPAT for 1H26 expected to be at least $90 million, up about 100% on 1H25
• Management fees for 1H26 anticipated at least $110 million
• Performance fees estimated to reach at least $115 million for 1H26
• Funds under management (FUM) grew 6% in the June quarter to approximately $21.4 billion
• Net FUM inflows hit a record $0.9 billion for the quarter, over $1.3 billion for the half

What else do investors need to know?

Regal Partners attributed strong performance fees to its PM Capital global strategy and robust flows across hedge funds, resources, and royalty strategies. The June quarter included the first close of the Taurus Mining Finance Fund III, raising around US$0.7 billion, contributing significantly to net inflows.

Partially offsetting these gains was the reduction in water entitlement assets under management, relating to the Commonwealth Government’s water buy-back program, which saw about $0.5 billion realised for institutional investors. Preliminary figures remain subject to final reviews and audit.

What’s next for Regal Partners?

The company will release its full 1H26 results on 24 August 2026 and remains focused on growing assets across its diverse investment strategies. Management flagged continued innovation in alternative investments and ongoing commitment to expanding Regal’s offering for institutional, family office, and private investors.

Investors can expect more details on outlook and strategy, as well as further updates on FUM and performance, at the official half-year results presentation.

Regal Partners share price snapshot

Over the past 12 months, Regal Partners shares have risen 7%, outperforming the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Regal Partners: Profit doubles and FUM hits record high appeared first on The Motley Fool Australia.

More reading

• How much do I need in my superannuation to get $1000 per week in passive income?
• 3 companies to own for a dividend yield above 5%
• Could this be the best ASX dividend share to buy now?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares received a nice boost yesterday after the company released Q2 2026 results.

Telix Pharmaceuticals is a pharmaceutical group specialising in the development and commercialisation of radio pharmaceuticals for the imaging and treatment of certain cancers.

What did the company report yesterday?

As The Motley Fool’s Bernd Struben reported, the company announced: 

• 21% year-on-year revenue boost to US$247 million (AU$353 million). 
• Second-quarter revenue rise of 7% from the prior quarter.
• The company’s Precision Medicine segment brought in US$202 million of that quarterly revenue, a 30% increase from Q2 2025 and up 9% from last quarter.

The company said it expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million.

Speaking on the results, Dr Christian Behrenbruch, Managing Director and Group CEO, said: 

We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution.

Following these results, Bell Potter released updated guidance on Telix shares. 

Solid growth 

Bell Potter’s report yesterday shows the broker sees the results largely as positive. 

Telix is growing faster than expected and appears to be gaining market share in PSMA imaging; it is confident enough to invest more in research and still expects strong underlying sales even without the one-off Regeneron payment.

Other than the half year result in August, the major upcoming catalyst is the FDA decision on approval of Pixclara for brain cancer imaging, due 11 September 2026. 

This pending approval represents a pivotal moment. Approval would likely generate a welcome re-rating. A second Complete Response Letter (CRL), depending on the nature of the contents, could be highly damaging as there are no other near to revenue pipeline products. 

In the clinic, we expect the FDA should clear the amended IND for TLX591 in the coming weeks, finally allowing recruitment of the Part 2 of this trial to commence recruitment in the US.

Healthy upside for Telix shares 

Based on this guidance, the team at Bell Potter has retained its buy recommendation for Telix shares. 

The broker has maintained its 12-month price target of $19. 

Based on yesterday’s closing price, this indicates upside potential of almost 26%. 

The post Are Telix shares a buy, hold or sell following results? appeared first on The Motley Fool Australia.

More reading

• Up 79% since February, why are Telix shares jumping higher again on Tuesday?
• Top 3 ASX healthcare stocks to watch
• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• These are the 10 most shorted ASX shares
• Down 9%: Is the rebound over for Telix shares?

Motley Fool contributor Aaron Bell has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Cleanaway Waste Management Ltd (ASX: CWY) share price is in focus today as the company announced a CFO transition and reaffirmed its FY26 earnings outlook, with underlying EBIT expected around $470 million.

What did Cleanaway Waste Management report?

• Appointment of Nigel Simonsz as incoming Chief Financial Officer, starting 27 July 2026
• Current CFO Paul Binfield stepping down, supporting transition through H1 FY27
• FY26 underlying EBIT expected to be approximately $470 million (midpoint of prior guidance)
• FY26 full year results set for release on 20 August 2026

What else do investors need to know?

Nigel Simonsz brings broad financial leadership experience from listed companies such as United Petroleum, Sigma Healthcare, and Australian Agricultural Company. The appointment follows an internal and external search, with an emphasis on continuity during Cleanaway’s reporting and strategy cycle.

Outgoing CFO Paul Binfield has served over five years, during which he guided the company through strategic acquisitions and helped shape Cleanaway’s Blueprint 2030 strategy. The board acknowledged his contribution and commitment to a smooth leadership handover.

What’s next for Cleanaway Waste Management?

Cleanaway will continue its focus on delivering Blueprint 2030, which centres on long-term sustainable growth and capital discipline. The company plans a structured CFO transition, maintaining stability while progressing its growth and operational strategies.

Further details on full-year financial performance and forward outlook are expected at the FY26 results announcement in August.

Cleanaway Waste Management share price snapshot

Over the past 12 months, Cleanaway shares have declined 20%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

View Original Announcement

The post Cleanaway Waste Management appoints new CFO and reaffirms FY26 earnings guidance appeared first on The Motley Fool Australia.

More reading

• Are Telix shares a buy, hold or sell following results?
• 3 reasons CBA shares are a screaming buy right now
• 8 things Aussies at age 58 need to know about the Age Pension asset test before they retire
• Beach Energy posts steady Q4 production and a resilient outlook
• Getting started with ASX ETFs? These 3 might be worth a look

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.